Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Eli Lilly Plans to Hire After Nabbing An Additional 6,000 Square Feet of Space in Crowded Kendall Square

BOSTON – Indianapolis-based Eli Lilly and Company (LLY) will take an additional 6,000 square feet of space in the crowded Kendall Square area magnifying the presence of the company’s new innovation center in the pharmaceutical hub of the east coast, the Boston Business Journal reported this morning.   This addition of space gives Eli Lilly […]

Read More »

Actelion in talks with ZS Pharma amid surge in biotech deal-making

Swiss drugmaker Actelion Ltd has initiated preliminary discussions with U.S. biotech company ZS Pharma Inc, marking the latest bout of deal-making in a healthcare sector that has seen a wave of recent takeovers. Actelion, Europe’s biggest biotech company, and ZS Pharma both issued statements late on Thursday stating that they had held preliminary discussions, but […]

Read More »

FDA panel recommends not approving Purdue’s opioid painkiller

A panel of outside advisers to the U.S. Food and Drug Administration on Thursday voted against approving Purdue Pharma’s opioid painkiller over concerns of overdosing. The recommendation follows comments from the health regulator’s staff on Tuesday on likely errors in administering the experimental drug. The agency’s staff on Wednesday had also highlighted that a rival […]

Read More »

Nine-Person Gencia Inks $500 Million Collaboration Deal with Takeda

Takeda Pharmaceutical Company, headquartered in Osaka, Japan, and Charlottesville, Va.-based Gencia LLC announced today a $500 million partnership deal. The two companies plan to work on a new class of small molecules as possible drugs for hematological and inflammatory diseases. The focus of the collaboration will be on Mitochondrial Agonists of the Glucocorticoid Receptor (MAGR), […]

Read More »

Agilent Acquires Seahorse Bioscience and its XF Technology for $235 Million

SANTA CLARA, Calif.—Pharma diagnostics company Agilent Technologies, Inc. (A) inked a $235 million deal to acquire privately-held Seahorse Bioscience to complement its mass spectrometry solutions and expand pharma offerings, the company announced this morning. Agilent said Seahorse’s technology enables researchers to “better understand cell health, function and signaling, and how the cell may be impacted […]

Read More »

Gilead Borrows $10 Billion, Spurring Acquisition Speculation

Foster City, Calif.-based Gilead Sciences, Inc. (GILD) announced Wednesday that it filed to borrow $10 billion in an underwritten, registered public offering. The offering will have six tranches that mature between 2018 and 2046.   The offering is planned to close Sept. 14, 2015 and are rated A- by Standard & Poor’s and A3 by […]

Read More »

Biogen Forges $544M Deal to Take on Celgene With a Rival Autoimmune Drug

Biogen, Inc., headquartered in Cambridge, Mass., announced today that it licensed MT-1303 from Mitsubishi Tanabe Pharma Corporation, located in Osaka, Japan. MT-1303 is being investigated in a number of autoimmune disorders, including multiple sclerosis (MS), ulcerative colitis, Crohn’s disease and others.   Biogen will obtain worldwide rights to MT-1303, excluding Asia. It will oversee global […]

Read More »

Celsion Updates Clinical Trial Data and Slashes 20% of Workforce

Lawrenceville, N.J.-based Celsion Corporation (CLSN) announced today that it completed the integration of its June 2014 acquisition of EGEN, Inc., and as part of the consolidation, had cut 15 to 20 percent of its staff and annual operational costs.   In June 2014, Celsion, which focuses on cancer drug development, acquired Huntsville, Ala.-based EGEN, Inc., […]

Read More »

GlaxoSmithKline lung drug fails to extend life in huge study

GlaxoSmithKline’s inhaled medicine Breo failed to prolong life in patients with chronic respiratory disease in a high-stakes clinical trial of 16,500 people, torpedoing hopes of a sales boost for the drug. Shares in Britain’s biggest drugmaker fell 1.5 percent on Wednesday, lagging a strong London market, in reaction to the news announced by the company […]

Read More »

Pacira sues FDA over pain drug marketing restrictions

Pacira Pharmaceuticals Inc on Tuesday filed a lawsuit seeking a court order allowing it to promote its post-surgery pain drug, Exparel, for a wide range of surgeries, which the U.S. Food and Drug Administration opposes. The lawsuit, filed in federal court in Manhattan, cites another New York judge’s recent decision allowing Irish drugmaker Amarin Plc […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom